Utility of a commercial immunoblot kit (BAG-Borrelia blot) in the diagnosis of the preliminary stages of XXXX .

@entity1 @entity7286 @entity3001 @entity5 @entity2069 @entity3963
The aim of this study was to evaluate the usefulness of a commercial immunoblot (IgG and IgM BAG-Borrelia blot) in the serologic diagnosis of the early stages of @entity3001 . A total of 42 sera from @entity1 with @entity3001 (24 @entity1 with localized early stage (LES) and 18 @entity1 with @entity5 ( @entity5 )) and 129 sera from @entity1 with non-Lyme diseases (specificity control sera) were studied. IgG anti- @entity3963 from @entity2069 s.l. was present in 95.2% of @entity1 followed by anti- @entity3963 /I PBi (16.7%), anti- @entity7286 (9.5%) and anti-OspA (9.5%). IgM anti- @entity3963 was present in 66.7% of @entity1 , @entity3963 /iPBi (54.8%) and OspC (33.3%). IgM against @entity7286 , OspA and OspC were more frequent in @entity5 @entity1 (16.7%, 27.8% and 44.4%) than in LES @entity1 (0.0%, 4.2% and 25.0%). In 4.8% of the cases no IgG bands were present and in 26.2% no IgM bands were present. With the exception of isolated @entity3963 bands (59.5%), no band pattern exceeded 17%. Using manufacturer's instructions, test sensitivity in diagnosis of the early stage of @entity3001 is 61.9%, specificity 98.4% and positive and negative predictive values 92.8% and 88.8% respectively. Applying the EUCALB 5, 6 or 7 rules sensitivity increased to 73.8% although specificity decreased to 89.9%. Of the 129 specific control sera, 41.8% presented IgG anti- @entity3963 and 10.8% IgM anti- @entity3963 . @entity1 with non-Lyme diseases that presented more IgG and IgM bands were those @entity1 with syphilis (88.2%), patients with anti-HIV antibodies (57.8%) and patients with anti-nuclear antibodies (ANA) (52.3%).
